Structured Immunity, Medigene AG Enter Collaboration

“We are delighted to begin this strategic collaboration with Medigene, a leader in immunotherapy, as together we aim to improve how lead TCR candidates are validated and optimized,” said David Hardwicke, co-founder and president of Structured Immunity. “We believe this partnership with Medigene will further showcase and validate our platform technology and demonstrate the value of structural immunology in TCR development.” 

 

Prof. Dolores Schendel, chief executive officer and chief scientific officer of Medigene AG, said, “We are excited to start this new collaboration with Structured Immunity that will focus on the structural interactions between a TCR and the corresponding MHC-peptide complex. As the recognition site between these two complexes is relatively small, it is necessary to determine the exact binding affinities of target peptides. We are convinced that SI’s technology can help us to select optimal and highly efficacious TCRs that have the potential to further enhance the efficacy and safety of our approach to bring highly beneficial cellular therapies to the market.”